{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:59:30Z","timestamp":1785495570083,"version":"3.56.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19762"],"award-info":[{"award-number":["25K19762"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19762"],"award-info":[{"award-number":["25K19762"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19762"],"award-info":[{"award-number":["25K19762"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19762"],"award-info":[{"award-number":["25K19762"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["25K19762"],"award-info":[{"award-number":["25K19762"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite recent advances in chemotherapy for colorectal cancer (CRC), chemotherapy-sensitive tumours often develop resistance to treatment, which remains a major clinical challenge. This acquired chemoresistance limits the efficacy of subsequent therapies and is associated with a poor prognosis. Therefore, this study identified the mechanisms of acquired chemoresistance in CRC and developed innovative targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>5-fluorouracil (5-FU)-and oxaliplatin (OX)-resistant CRC cells were established through long-term exposure to anticancer drugs, and RNA sequencing (RNA-seq) was performed. RNA-seq data integrated analysis from resistant cells and public single-cell RNA-seq datasets from clinical CRC samples was conducted to identify key drivers of chemoresistance. Prognostic significance was evaluated by immunohistochemical analysis of liver metastasis specimens from patients with CRC who underwent curative resection of the primary tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Chemotherapy exposure enriched high stemness and activated TGF-\u03b2 signalling. GDF15 was identified as a key molecule upregulated in both chemoresistant and high-stemness cells. Clinically, high GDF15 expression is associated with early recurrence and poor prognosis. Functional assays demonstrated that GDF15 overexpression promoted chemoresistance, stemness, and migratory capacity of CRC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GDF15 promotes chemoresistance in CRC by promoting stem cell-like properties. These findings provide insights into therapeutic strategies for overcoming acquired chemoresistance and improving outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03379-0","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:34:21Z","timestamp":1778607261000},"page":"659-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GDF15 promotes 5-Fluorouracil and Oxaliplatin resistance by promoting stem cell-like phenotype in colorectal cancer"],"prefix":"10.1038","volume":"135","author":[{"given":"Masahiro","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6616-9069","authenticated-orcid":false,"given":"Tsuyoshi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Chinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Haruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunobu","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hamabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikatsu","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Tobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-9974","authenticated-orcid":false,"given":"Koshi","family":"Mimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"3379_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"key":"3379_CR2","doi-asserted-by":"publisher","first-page":"852","DOI":"10.6004\/jnccn.2018.0060","volume":"16","author":"AB Benson","year":"2018","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Anal carcinoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:852\u201371. https:\/\/doi.org\/10.6004\/jnccn.2018.0060.","journal-title":"J Natl Compr Canc Netw"},{"key":"3379_CR3","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"key":"3379_CR4","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","volume":"25","author":"DJ Sargent","year":"2007","unstructured":"Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25:4569\u201374. https:\/\/doi.org\/10.1200\/JCO.2006.10.4323.","journal-title":"J Clin Oncol"},{"key":"3379_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1200\/JCO.19.00281","volume":"37","author":"C Lieu","year":"2019","unstructured":"Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Duration of oxaliplatin-containing adjuvant therapy for stage iii colon cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1436\u201347. https:\/\/doi.org\/10.1200\/JCO.19.00281.","journal-title":"J Clin Oncol"},{"key":"3379_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40:892\u2013910. https:\/\/doi.org\/10.1200\/JCO.21.02538.","journal-title":"J Clin Oncol"},{"key":"3379_CR7","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1007\/s12094-024-03559-5","volume":"26","author":"C Pericay","year":"2024","unstructured":"Pericay C, Montagut C, Reina JJ, Melian M, Alcaide J, Tarazona N, et al. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023). Clin Transl Oncol. 2024;26:2812\u201325. https:\/\/doi.org\/10.1007\/s12094-024-03559-5.","journal-title":"Clin Transl Oncol"},{"key":"3379_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115139","volume":"214","author":"H Hirano","year":"2025","unstructured":"Hirano H, Kataoka K, Yamaguchi T, Wagner AD, Shimada Y, Inomata M, et al. Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A). Eur J Cancer. 2025;214:115139. https:\/\/doi.org\/10.1016\/j.ejca.2024.115139.","journal-title":"Eur J Cancer"},{"key":"3379_CR9","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.21.02628","volume":"40","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, et al. Final analysis of 3 versus 6 months of adjuvant oxaliplatin and fluoropyrimidine-based therapy in patients with stage III colon cancer: the randomized phase III ACHIEVETrial. J Clin Oncol. 2022;40:3419\u201329. https:\/\/doi.org\/10.1200\/JCO.21.02628.","journal-title":"J Clin Oncol"},{"key":"3379_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1245\/s10434-014-4094-7","volume":"22","author":"H Uetake","year":"2015","unstructured":"Uetake H, Yasuno M, Ishiguro M, Kameoka S, Shimada Y, Takahashi K, et al. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808). Ann Surg Oncol. 2015;22:908\u201315. https:\/\/doi.org\/10.1245\/s10434-014-4094-7.","journal-title":"Ann Surg Oncol"},{"key":"3379_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ctrv.2015.10.012","volume":"42","author":"E Esin","year":"2016","unstructured":"Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: a systematic review. Cancer Treat Rev. 2016;42:82\u201390. https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.012.","journal-title":"Cancer Treat Rev"},{"key":"3379_CR12","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1053\/j.gastro.2024.10.046","volume":"168","author":"C Pilati","year":"2025","unstructured":"Pilati C, Soulabaille A, Gallois C, Blons H, Cayre A, Sroussi M, et al. ERBB2 comprehensive profiling and prognostication in stage III colon cancer: findings from PETACC8 and IDEA-France cohorts. Gastroenterology. 2025;168:714\u201324.e4. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.046.","journal-title":"Gastroenterology"},{"key":"3379_CR13","doi-asserted-by":"publisher","first-page":"8887","DOI":"10.18632\/oncotarget.22322","volume":"9","author":"N Wu","year":"2018","unstructured":"Wu N, Fesler A, Liu H, Ju J. Development of novel miR-129 mimics with enhanced efficacy to eliminate chemoresistant colon cancer stem cells. Oncotarget. 2018;9:8887\u201397. https:\/\/doi.org\/10.18632\/oncotarget.22322.","journal-title":"Oncotarget"},{"key":"3379_CR14","doi-asserted-by":"publisher","unstructured":"Haynes J, Manogaran P. Mechanisms and strategies to overcome drug resistance in colorectal cancer. Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms26051988.","DOI":"10.3390\/ijms26051988"},{"key":"3379_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532\u20136. https:\/\/doi.org\/10.1038\/nature11156.","journal-title":"Nature"},{"key":"3379_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","volume":"3","author":"A Bardelli","year":"2013","unstructured":"Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0558.","journal-title":"Cancer Discov"},{"key":"3379_CR17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","volume":"4","author":"S Misale","year":"2014","unstructured":"Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269\u201380. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0462.","journal-title":"Cancer Discov"},{"key":"3379_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754220","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Wu W, Zheng Z, Chi P. Exploring better strategies for RAS mutation-associated EGFR-targeted resistance in colorectal cancer: from the perspective of cancer community ecology. Front Oncol. 2021;11:754220. https:\/\/doi.org\/10.3389\/fonc.2021.754220.","journal-title":"Front Oncol"},{"key":"3379_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275\u201392. https:\/\/doi.org\/10.1002\/path.1706.","journal-title":"J Pathol"},{"key":"3379_CR20","doi-asserted-by":"publisher","unstructured":"Wang Q, Shen X, Chen G, Du J. Drug resistance in colorectal cancer: from mechanism to clinic. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14122928.","DOI":"10.3390\/cancers14122928"},{"key":"3379_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.celrep.2018.03.086","volume":"23","author":"J Saltz","year":"2018","unstructured":"Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, et al. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep. 2018;23:181\u201393.e7. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.086.","journal-title":"Cell Rep"},{"key":"3379_CR22","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021;184:4734\u201352.e20. https:\/\/doi.org\/10.1016\/j.cell.2021.08.003.","journal-title":"Cell"},{"key":"3379_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105102","volume":"103","author":"M Hashimoto","year":"2024","unstructured":"Hashimoto M, Kojima Y, Sakamoto T, Ozato Y, Nakano Y, Abe T, et al. Spatial and single-cell colocalisation analysis reveals MDK-mediated immunosuppressive environment with regulatory T cells in colorectal carcinogenesis. EBioMedicine. 2024;103:105102. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105102.","journal-title":"EBioMedicine"},{"key":"3379_CR24","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41588-022-01157-1","volume":"54","author":"D Cui Zhou","year":"2022","unstructured":"Cui Zhou D, Jayasinghe RG, Chen S, Herndon JM, Iglesia MD, Navale P, et al. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Nat Genet. 2022;54:1390\u2013405. https:\/\/doi.org\/10.1038\/s41588-022-01157-1.","journal-title":"Nat Genet"},{"key":"3379_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101231","volume":"4","author":"P Qin","year":"2023","unstructured":"Qin P, Chen H, Wang Y, Huang L, Huang K, Xiao G, et al. Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics. Cell Rep Med. 2023;4:101231. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101231.","journal-title":"Cell Rep Med"},{"key":"3379_CR26","doi-asserted-by":"publisher","unstructured":"Yang C, Guo L, Du J, Zhang Q, Zhang L. SPINK1 overexpression correlates with hepatocellular carcinoma treatment resistance revealed by single cell RNA-sequencing and spatial transcriptomics. Biomolecules. 2024;14. https:\/\/doi.org\/10.3390\/biom14030265.","DOI":"10.3390\/biom14030265"},{"key":"3379_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/jso.27590","volume":"129","author":"T Beppu","year":"2024","unstructured":"Beppu T, Yamamura K, Imai K, Hayashi H, Miyamoto Y. Recurrence-risk stratification using the Beppu score and selection of perioperative chemotherapy for colorectal liver metastases. J Surg Oncol. 2024;129:893\u2013900. https:\/\/doi.org\/10.1002\/jso.27590.","journal-title":"J Surg Oncol"},{"key":"3379_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41421-021-00312-y","volume":"7","author":"LH Che","year":"2021","unstructured":"Che LH, Liu JW, Huo JP, Luo R, Xu RM, He C, et al. A single-cell atlas of liver metastases of colorectal cancer reveals reprogramming of the tumor microenvironment in response to preoperative chemotherapy. Cell Discov. 2021;7:80 https:\/\/doi.org\/10.1038\/s41421-021-00312-y.","journal-title":"Cell Discov"},{"key":"3379_CR29","doi-asserted-by":"publisher","first-page":"33403","DOI":"10.18632\/oncotarget.23607","volume":"9","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;9:33403\u201315. https:\/\/doi.org\/10.18632\/oncotarget.23607.","journal-title":"Oncotarget"},{"key":"3379_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2159-8290.CD-21-0316","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12:134\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0316.","journal-title":"Cancer Discov"},{"key":"3379_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.cels.2024.01.007","volume":"15","author":"Y Kojima","year":"2024","unstructured":"Kojima Y, Mii S, Hayashi S, Hirose H, Ishikawa M, Akiyama M, et al. Single-cell colocalization analysis using a deep generative model. Cell Syst. 2024;15:180\u201392.e7. https:\/\/doi.org\/10.1016\/j.cels.2024.01.007.","journal-title":"Cell Syst"},{"key":"3379_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13046-018-0836-x","volume":"37","author":"MH Cai","year":"2018","unstructured":"Cai MH, Xu XG, Yan SL, Sun Z, Ying Y, Wang BK, et al. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling. J Exp Clin Cancer Res. 2018;37:151 https:\/\/doi.org\/10.1186\/s13046-018-0836-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"3379_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106478","volume":"26","author":"H Itakura","year":"2023","unstructured":"Itakura H, Hata T, Okuzaki D, Takeda K, Iso K, Qian Y, et al. Tumor-suppressive role of the. iScience. 2023;26:106478. https:\/\/doi.org\/10.1016\/j.isci.2023.106478.","journal-title":"iScience"},{"key":"3379_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41416-020-0758-1","volume":"122","author":"Y Morimoto","year":"2020","unstructured":"Morimoto Y, Mizushima T, Wu X, Okuzaki D, Yokoyama Y, Inoue A, et al. miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells. Br J Cancer. 2020;122:1037\u201349. https:\/\/doi.org\/10.1038\/s41416-020-0758-1.","journal-title":"Br J Cancer"},{"key":"3379_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/bjc.2016.255","volume":"115","author":"C Bellomo","year":"2016","unstructured":"Bellomo C, Caja L, Moustakas A. Transforming growth factor \u03b2 as regulator of cancer stemness and metastasis. Br J Cancer. 2016;115:761\u20139. https:\/\/doi.org\/10.1038\/bjc.2016.255.","journal-title":"Br J Cancer"},{"key":"3379_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s1097-2765(01)00430-0","volume":"9","author":"XH Feng","year":"2002","unstructured":"Feng XH, Liang YY, Liang M, Zhai W, Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell. 2002;9:133\u201343. https:\/\/doi.org\/10.1016\/s1097-2765(01)00430-0.","journal-title":"Mol Cell"},{"key":"3379_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13287-022-02913-0","volume":"13","author":"H Zheng","year":"2022","unstructured":"Zheng H, Liu H, Li H, Dou W, Wang J, Zhang J, et al. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer. Stem Cell Res Ther. 2022;13:244. https:\/\/doi.org\/10.1186\/s13287-022-02913-0.","journal-title":"Stem Cell Res Ther"},{"key":"3379_CR38","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3892\/ol.2023.14049","volume":"26","author":"T Ling","year":"2023","unstructured":"Ling T, Zhang J, Ding F, Ma L. Role of growth differentiation factor 15 in cancer cachexia (Review). Oncol Lett. 2023;26:462. https:\/\/doi.org\/10.3892\/ol.2023.14049.","journal-title":"Oncol Lett"},{"key":"3379_CR39","first-page":"8506","volume":"7","author":"W Huang","year":"2014","unstructured":"Huang W, Zhu S, Liu Q, Li C, Li L. Placenta growth factor promotes migration through regulating epithelial-mesenchymal transition-related protein expression in cervical cancer. Int J Clin Exp Pathol. 2014;7:8506\u201319.","journal-title":"Int J Clin Exp Pathol"},{"key":"3379_CR40","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/0008-5472.CAN-19-2660","volume":"80","author":"AA Abdul Pari","year":"2020","unstructured":"Abdul Pari AA, Singhal M, H\u00fcbers C, Mogler C, Schieb B, Gampp A, et al. Tumor cell-derived angiopoietin-2 promotes metastasis in melanoma. Cancer Res. 2020;80:2586\u201398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2660.","journal-title":"Cancer Res"},{"key":"3379_CR41","doi-asserted-by":"publisher","first-page":"946","DOI":"10.5966\/sctm.2013-0055","volume":"2","author":"J Corre","year":"2013","unstructured":"Corre J, H\u00e9braud B, Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role?. Stem Cells Transl Med. 2013;2:946\u201352. https:\/\/doi.org\/10.5966\/sctm.2013-0055.","journal-title":"Stem Cells Transl Med"},{"key":"3379_CR42","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.molonc.2014.05.003","volume":"8","author":"BO Van Emburgh","year":"2014","unstructured":"Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014;8:1084\u201394. https:\/\/doi.org\/10.1016\/j.molonc.2014.05.003.","journal-title":"Mol Oncol"},{"key":"3379_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02005-y","volume":"23","author":"H Gao","year":"2024","unstructured":"Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L, et al. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options. Mol Cancer. 2024;23:88. https:\/\/doi.org\/10.1186\/s12943-024-02005-y.","journal-title":"Mol Cancer"},{"key":"3379_CR44","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-16-1863","volume":"23","author":"F Pietrantonio","year":"2017","unstructured":"Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, et al. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2017;23:2414\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1863.","journal-title":"Clin Cancer Res"},{"key":"3379_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33172-5","volume":"13","author":"RM Johnson","year":"2022","unstructured":"Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, et al. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nat Commun. 2022;13:5478. https:\/\/doi.org\/10.1038\/s41467-022-33172-5.","journal-title":"Nat Commun"},{"key":"3379_CR46","doi-asserted-by":"publisher","unstructured":"Yang W, Zhang M, Zhang TX, Liu JH, Hao MW, Yan X, et al. YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis. JCI Insight. 2024;9. https:\/\/doi.org\/10.1172\/jci.insight.178535.","DOI":"10.1172\/jci.insight.178535"},{"key":"3379_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1461190","volume":"14","author":"G Yayli","year":"2024","unstructured":"Yayli G, Tokofsky A, Nayar U. The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways. Front Oncol. 2024;14:1461190. https:\/\/doi.org\/10.3389\/fonc.2024.1461190.","journal-title":"Front Oncol"},{"key":"3379_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd1984","volume":"5","author":"G Szak\u00e1cs","year":"2006","unstructured":"Szak\u00e1cs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219\u201334. https:\/\/doi.org\/10.1038\/nrd1984.","journal-title":"Nat Rev Drug Discov"},{"key":"3379_CR49","first-page":"361","volume":"33","author":"S Tanaka","year":"2008","unstructured":"Tanaka S, Sakai A, Kimura K, Yoshida H, Fushitani H, Ogata A, et al. Proteomic analysis of the basic proteins in 5-fluorouracil resistance of human colon cancer cell line using the radical-free and highly reducing method of two-dimensional polyacrylamide gel electrophoresis. Int J Oncol. 2008;33:361\u201370.","journal-title":"Int J Oncol"},{"key":"3379_CR50","doi-asserted-by":"publisher","unstructured":"Francipane MG, Bulanin D, Lagasse E. Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20081817.","DOI":"10.3390\/ijms20081817"},{"key":"3379_CR51","doi-asserted-by":"publisher","unstructured":"Ramzy GM, Boschung L, Koessler T, Delucinge-Vivier C, Docquier M, McKee TA, et al. FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells. Cancers (Basel). 2022;14. https:\/\/doi.org\/10.3390\/cancers14194812.","DOI":"10.3390\/cancers14194812"},{"key":"3379_CR52","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.ejca.2012.12.002","volume":"49","author":"D Yamada","year":"2013","unstructured":"Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H, et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer. 2013;49:1725\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.002.","journal-title":"Eur J Cancer"},{"key":"3379_CR53","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/bjc.2014.454","volume":"111","author":"S Hasegawa","year":"2014","unstructured":"Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer. 2014;111:1572\u201380. https:\/\/doi.org\/10.1038\/bjc.2014.454.","journal-title":"Br J Cancer"},{"key":"3379_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216997","volume":"595","author":"Y Ito","year":"2024","unstructured":"Ito Y, Yamada D, Kobayashi S, Sasaki K, Iwagami Y, Tomimaru Y, et al. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. Cancer Lett. 2024;595:216997. https:\/\/doi.org\/10.1016\/j.canlet.2024.216997.","journal-title":"Cancer Lett"},{"key":"3379_CR55","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J. TGF\u03b2 signalling in context. Nat Rev Mol Cell Biol. 2012;13:616\u201330. https:\/\/doi.org\/10.1038\/nrm3434.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3379_CR56","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/j.1349-7006.2008.00914.x","volume":"99","author":"H Ishii","year":"2008","unstructured":"Ishii H, Iwatsuki M, Ieta K, Ohta D, Haraguchi N, Mimori K, et al. Cancer stem cells and chemoradiation resistance. Cancer Sci. 2008;99:1871\u20137. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00914.x.","journal-title":"Cancer Sci"},{"key":"3379_CR57","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3892\/ijo.2013.1837","volume":"42","author":"S Nishikawa","year":"2013","unstructured":"Nishikawa S, Konno M, Hamabe A, Hasegawa S, Kano Y, Ohta K, et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol. 2013;42:1437\u201342. https:\/\/doi.org\/10.3892\/ijo.2013.1837.","journal-title":"Int J Oncol"},{"key":"3379_CR58","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","volume":"160","author":"N Oshimori","year":"2015","unstructured":"Oshimori N, Oristian D, Fuchs E. TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell. 2015;160:963\u201376. https:\/\/doi.org\/10.1016\/j.cell.2015.01.043.","journal-title":"Cell"},{"key":"3379_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03678-1","volume":"25","author":"Y Jia","year":"2025","unstructured":"Jia Y, Zhang L, Zhou W, Chen S, Zhang H, Liu L, et al. Rack1 promotes breast cancer stemness properties and tumorigenesis through the E2F1-SOX2 axis. Cancer Cell Int. 2025;25:40. https:\/\/doi.org\/10.1186\/s12935-025-03678-1.","journal-title":"Cancer Cell Int"},{"key":"3379_CR60","doi-asserted-by":"publisher","unstructured":"Zhang G, Zhang X, Pan W, Chen X, Wan L, Liu C, et al. Dissecting the spatial and single-cell transcriptomic architecture of cancer stem cell niche driving tumor progression in gastric cancer. Adv Sci (Weinh). 2025:e2413019. https:\/\/doi.org\/10.1002\/advs.202413019.","DOI":"10.1002\/advs.202413019"},{"key":"3379_CR61","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.stem.2025.01.002","volume":"32","author":"T Peng","year":"2025","unstructured":"Peng T, Ma X, Hua W, Wang C, Chu Y, Sun M, et al. Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. Cell Stem Cell. 2025;32:652\u201369.e11. https:\/\/doi.org\/10.1016\/j.stem.2025.01.002.","journal-title":"Cell Stem Cell"},{"key":"3379_CR62","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-13-1854","volume":"20","author":"Y Touil","year":"2014","unstructured":"Touil Y, Igoudjil W, Corvaisier M, Dessein AF, Vandomme J, Mont\u00e9 D, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes\/YAP axis. Clin Cancer Res. 2014;20:837\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1854.","journal-title":"Clin Cancer Res"},{"key":"3379_CR63","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","volume":"178","author":"HH Luan","year":"2019","unstructured":"Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM, et al. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. Cell. 2019;178:1231\u201344.e11. https:\/\/doi.org\/10.1016\/j.cell.2019.07.033.","journal-title":"Cell"},{"key":"3379_CR64","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1158\/1078-0432.ccr-03-0165","volume":"10","author":"J Koopmann","year":"2004","unstructured":"Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386\u201392. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0165.","journal-title":"Clin Cancer Res"},{"key":"3379_CR65","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3233\/CBM-170792","volume":"21","author":"M Vocka","year":"2018","unstructured":"Vocka M, Langer D, Fryba V, Petrtyl J, Hanus T, Kalousova M, et al. Growth\/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer. Cancer Biomark. 2018;21:869\u201374. https:\/\/doi.org\/10.3233\/CBM-170792.","journal-title":"Cancer Biomark"},{"key":"3379_CR66","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18632\/oncotarget.6205","volume":"7","author":"C Li","year":"2016","unstructured":"Li C, Wang J, Kong J, Tang J, Wu Y, Xu E, et al. GDF15 promotes EMT and metastasis in colorectal cancer. Oncotarget. 2016;7:860\u201372. https:\/\/doi.org\/10.18632\/oncotarget.6205.","journal-title":"Oncotarget"},{"key":"3379_CR67","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/bjc.2011.112","volume":"104","author":"U Wallin","year":"2011","unstructured":"Wallin U, Glimelius B, Jirstr\u00f6m K, Darmanis S, Nong RY, Pont\u00e9n F, et al. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer. 2011;104:1619\u201327. https:\/\/doi.org\/10.1038\/bjc.2011.112.","journal-title":"Br J Cancer"},{"key":"3379_CR68","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s13402-024-00918-w","volume":"47","author":"H Lin","year":"2024","unstructured":"Lin H, Luo Y, Gong T, Fang H, Li H, Ye G, et al. GDF15 induces chemoresistance to oxaliplatin by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis in colorectal cancer. Cell Oncol (Dordr). 2024;47:1149\u201365. https:\/\/doi.org\/10.1007\/s13402-024-00918-w.","journal-title":"Cell Oncol (Dordr)"},{"key":"3379_CR69","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/blood-2013-08-524025","volume":"123","author":"T Tanno","year":"2014","unstructured":"Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel PL, Matthews G, et al. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2014;123:725\u201333. https:\/\/doi.org\/10.1182\/blood-2013-08-524025.","journal-title":"Blood"},{"key":"3379_CR70","doi-asserted-by":"publisher","first-page":"24869","DOI":"10.18632\/oncotarget.15276","volume":"8","author":"A Sasahara","year":"2017","unstructured":"Sasahara A, Tominaga K, Nishimura T, Yano M, Kiyokawa E, Noguchi M, et al. An autocrine\/paracrine circuit of growth differentiation factor (GDF) 15 has a role for maintenance of breast cancer stem-like cells. Oncotarget. 2017;8:24869\u201381. https:\/\/doi.org\/10.18632\/oncotarget.15276.","journal-title":"Oncotarget"},{"key":"3379_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41420-020-00395-8","volume":"7","author":"S Zhu","year":"2021","unstructured":"Zhu S, Yang N, Guan Y, Wang X, Zang G, Lv X, et al. GDF15 promotes glioma stem cell-like phenotype via regulation of ERK1\/2-c-Fos-LIF signaling. Cell Death Discov. 2021;7:3 https:\/\/doi.org\/10.1038\/s41420-020-00395-8.","journal-title":"Cell Death Discov"},{"key":"3379_CR72","doi-asserted-by":"publisher","first-page":"63937","DOI":"10.18632\/oncotarget.11570","volume":"7","author":"F Luo","year":"2016","unstructured":"Luo F, Li J, Wu S, Wu X, Chen M, Zhong X, et al. Comparative profiling between primary colorectal carcinomas and metastases identifies heterogeneity on drug resistance. Oncotarget. 2016;7:63937\u201349. https:\/\/doi.org\/10.18632\/oncotarget.11570.","journal-title":"Oncotarget"},{"key":"3379_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1542197","volume":"16","author":"Q Yuan","year":"2025","unstructured":"Yuan Q, Jia L, Yang J, Li W. The role of macrophages in liver metastasis: mechanisms and therapeutic prospects. Front Immunol. 2025;16:1542197. https:\/\/doi.org\/10.3389\/fimmu.2025.1542197.","journal-title":"Front Immunol"},{"key":"3379_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2254-1","volume":"11","author":"X Shen","year":"2020","unstructured":"Shen X, Hu X, Mao J, Wu Y, Liu H, Shen J, et al. The long noncoding RNA TUG1 is required for TGF-\u03b2\/TWIST1\/EMT-mediated metastasis in colorectal cancer cells. Cell Death Dis. 2020;11:65. https:\/\/doi.org\/10.1038\/s41419-020-2254-1.","journal-title":"Cell Death Dis"},{"key":"3379_CR75","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s13046-024-03114-8","volume":"43","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Yang Y, Qi X, Cui P, Kang Y, Liu H, et al. SLC14A1 and TGF-\u03b2 signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasis. J Exp Clin Cancer Res. 2024;43:208. https:\/\/doi.org\/10.1186\/s13046-024-03114-8.","journal-title":"J Exp Clin Cancer Res"},{"key":"3379_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217452","volume":"612","author":"Y Zhan","year":"2025","unstructured":"Zhan Y, Sun D, Gao J, Gao Q, Lv Y, Du T, et al. Single-cell transcriptomics reveals intratumor heterogeneity and the potential roles of cancer stem cells and myCAFs in colorectal cancer liver metastasis and recurrence. Cancer Lett. 2025;612:217452. https:\/\/doi.org\/10.1016\/j.canlet.2025.217452.","journal-title":"Cancer Lett"},{"key":"3379_CR77","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","volume":"26","author":"R Suriben","year":"2020","unstructured":"Suriben R, Chen M, Higbee J, Oeffinger J, Ventura R, Li B, et al. Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice. Nat Med. 2020;26:1264\u201370. https:\/\/doi.org\/10.1038\/s41591-020-0945-x.","journal-title":"Nat Med"},{"key":"3379_CR78","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa007","volume":"41","author":"SM Lockhart","year":"2020","unstructured":"Lockhart SM, Saudek V, O\u2019Rahilly S. GDF15: A Hormone Conveying Somatic Distress to the Brain. Endocr Rev. 2020;41:bnaa007. https:\/\/doi.org\/10.1210\/endrev\/bnaa007.","journal-title":"Endocr Rev"},{"key":"3379_CR79","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3389\/fimmu.2020.00951","volume":"11","author":"J Wischhusen","year":"2020","unstructured":"Wischhusen J, Melero I, Fridman WH. Growth\/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front Immunol. 2020;11:951. https:\/\/doi.org\/10.3389\/fimmu.2020.00951.","journal-title":"Front Immunol"},{"key":"3379_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.molimm.2025.07.006","volume":"185","author":"R Li","year":"2025","unstructured":"Li R, Wu H, Ran F, He Y, Sun H, Peng W, et al. GDF15 activates the PI3K\/AKT pathway to mediate macrophage M2 polarization to promote prostate cancer resistance to docetaxel. Mol Immunol. 2025;185:27\u201338. https:\/\/doi.org\/10.1016\/j.molimm.2025.07.006.","journal-title":"Mol Immunol"},{"key":"3379_CR81","first-page":"2642","volume":"9","author":"DA Brown","year":"2003","unstructured":"Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003;9:2642\u201350.","journal-title":"Clin Cancer Res"},{"key":"3379_CR82","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.prp.2015.08.004","volume":"211","author":"J Wang","year":"2015","unstructured":"Wang J, Li W, Wang Y, Li C, Ding M, Zhang H, et al. The H6D genetic variation of GDF15 is associated with genesis, progress and prognosis in colorectal cancer. Pathol Res Pract. 2015;211:845\u201350. https:\/\/doi.org\/10.1016\/j.prp.2015.08.004.","journal-title":"Pathol Res Pract"},{"key":"3379_CR83","doi-asserted-by":"publisher","first-page":"24892","DOI":"10.18632\/oncotarget.15279","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Yang Z, Tian H, Li Y, Li M, Zhao W, et al. Circulating MIC-1\/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer. Oncotarget. 2017;8:24892\u2013901. https:\/\/doi.org\/10.18632\/oncotarget.15279.","journal-title":"Oncotarget"},{"key":"3379_CR84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03379-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03379-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:17:55Z","timestamp":1785493075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03379-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8,20]]}},"alternative-id":["3379"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03379-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Approval of the study protocol by an institutional review board: the study was approved by the University of Osaka Institutional Review Board (approval #19020-3) and was performed in accordance with the tenets of the Declaration of Helsinki. Informed consent was obtained in the form of opt-out on the website (\n                      \n                      ).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}